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A B S T R A C T  
Background: Pathological changes that mainly affect prostate gland are prostatitis, benign prostatic hyperplasia (BPH) and 
cancerous lesions. Digital rectal examination (DRE), Transrectal Ultrasonography (TUS), and prostate specific antigen (PSA) 
followed by histopathological examination, are routinely used tests for diagnosis of prostate lesions. The aim of the present study is 
to determine the role of serum PSA levels in differentially diagnosing the different types of prostate lesions. 
Material and Methods: This retrospective (observational) study was conducted in Ibn-e-Sina Hospital Multan. Data of 2189 
patients who were operated from 2007 to 2017 due to prostatic lesions were included in this analysis. Patients with BPH, prostatitis, 
prostate carcinoma and Prostatic Intraepithelial Neoplasia (PIN) were grouped according to serum PSA levels (ranging from 0 to 
>100 ng/ml) into five groups. Frequencies and percentages were calculated for different histopathological findings. Association of 
PSA levels with different histological patterns was determined with chi-square test with P-value < 0.05 taken as significant difference. 
Results: Mean age of patients was 62.45+10.64 years. On histopathology, BPH was diagnosed in 1676 (76.56%) patients, 
prostatitis in 133 (6.07%), carcinoma in 378 (17.26%) and PIN in 02 (0.09%) patients, respectively. Serum PSA levels of 4.01-10 
ng/ml were found in 1050 (62.64%) BPH patients and in 59 (44.36%) prostatitis patients. Serum PSA levels of 10.01-20 ng/ml were 
found in only 40 (2.4%) BPH patients, 47 (35.33%) prostatitis patients, 22 (5.82%) carcinoma patients and in 1 (50.0%) PIN patient. 
Serum PSA levels of 20.01-100 ng/ml were found in 32 (1.9%) BPH patients, 11 (8.27%) prostatitis patients, 302 (79.89%) 
carcinoma patients, and in 1 (50.0%) PIN patient. Serum PSA levels of >100 ng/ml were absent in patients with BPH and PIN, and 
present in 1 (0.75%) prostatitis and 54 (14.28%) carcinoma patients. 
Conclusion: Benign prostatic hyperplasia was the commonest lesion in our patients (76.56%) with serum PSA levels >10 ng/ml 
reported in all patients with prostate carcinoma and prostatic intraepithelial neoplasia (PIN) patients. 
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I n t r o d u c t i o n  
 
Benign prostatic hyperplasia (BPH), prostatitis and 
carcinoma are three most common prostate lesions with 
BPH as the commonest lesion, affecting 210 million of the 
male population worldwide.1 BPH is now considered a 
normal part of aging as it is present in 100% male 
population of age >80 years.1 Cancer of prostate is 
ranked as the second most common cancer and fifth 
leading cause of death due to cancer in males.2  
 
Pathological changes that mainly affect prostate gland are 
prostatitis, benign prostatic hyperplasia (BPH), PIN and 
prostate cancer. There is an increasing incidence of 
prostate cancer and BPH with increasing age, however 
BPH is reported as the commonest lesion.3 Histological 
findings of BPH are present in 20% of males at the age of 
40 years, in 70% at 60 years and in 90% by the time they 
reach 80 years of age.3 Peak incidence is reported in the 
sixth decade of life in the Pakistani population.4 While in 
some other countries the peak incidence is in the ninth 
decade of life.5 In addition to age, other risk factors of 
prostate lesions are those concerned with metabolic 
disorders such as diabetes, obesity, dyslipidemia and 
physical inactivity.4 
 
Digital rectal examination (DRE), Transrectal 
Ultrasonography, and prostate specific antigen (PSA) 
followed by histopathological examination are routinely 
used tests for the diagnosis of prostate lesions.6 PSA is 
physiologically secreted in semen in high concentrations 
for liquefication of semen coagulum.7 PSA is also found in 
human blood plasma/serum and is widely used for 
detection of prostate pathology since 1988. PSA levels 
increase in proportion with disease severity and studies 
have found that a steep increase in PSA level increases 
the likelihood of diagnosis of prostate cancer.8,9  
 
Serum PSA levels <4.0 ng/ml in patients with prostate 
lesions are considered normal, 4-10 ng/ml are border line 
while >10 ng/ml are considered to have a high risk for 
malignancy. PSA levels are only used to diagnose lesions 
and histopathological examination is needed to 
differentiate different types of lesions.  
 
The aim of the present study was to determine the role of 
serum PSA levels in differentially diagnosing the different 
histopathological types of prostate lesions. 
M a t e r i a l  a n d  M e t h o d s  
This retrospective study was conducted in Ibn-e-Sina 
Hospital Multan. Data of 2189 patients who were operated 
from 2007 to 2017 due to prostatic lesions were included 
in this analysis. Patients with inadequate biopsy 
specimens were excluded. Departmental and ERB 
approval was taken before analyzing the data. Patients 
with BPH, prostatitis, prostate carcinoma and prostatic 
intraepithelial neoplasia (PIN) were grouped according to 
serum PSA levels (ranging from 0 - >100 ng/ml) into five 
groups Serum PSA levels done before surgery were 
noted for each patient. Biopsy specimens were brought to 
the histopathology laboratory in 10% formalin solution for 
confirmation of the diagnosis of prostate lesions. These 
sections were then stained with eosin and hematoxylin 
stain and slides were evaluated microscopically for 
determination of types of lesions. Consultant 
histopathologist made the final diagnosis of prostate 
lesions.  
 
All the data was entered in SPSS version 21. Frequencies 
and percentages were calculated for different 
histopathological findings. Association of serum PSA 
levels with different histopathological patterns was 
determined using chi-square test with P-value < 0.05 
taken as a significant difference 
 
R e s u l t s  
Mean age of all patients was 62.45+10.64 years. On 
histopathology, BPH was diagnosed in 1676 (76.56%) 
patients, prostatitis in 133 (6.07%), carcinoma in 378 
(17.26%) and PIN in 02 (0.09%) patients only (Table I). 
On comparison of serum PSA levels with various types of 
histopathological lesions, almost all patients of BPH, and 
about 55% patients of prostatitis had PSA levels within 
the range of 0-10 ng/ml.  
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Table I. Frequency Distribution of Histopathological Lesions 
Type of Lesion Frequency 
(n) 
Percentage 
(%) 
BPH 1676 76.56 
Prostatitis  133 6.07 
Acute Prostatitis 26 1.18 
Chronic Prostatitis 83 3.79 
Acute and Chronic Prostatitis 24 1.09 
Carcinoma  378 17.26 
Adenocarcinoma  364 16.62 
Transitional cell carcinoma 01 0.045 
Mucinous Adenocarcinoma 02 0.09 
Adenoid basaloid tumor 01 0.045 
Rhabdomyosarioma 01 0.045 
Small cell tumor 01 0.045 
Squamous cell carcinoma 03 0.14 
Infiltration by TCC 02 0.09 
Large cell type 01 0.045 
Sarcomatoid varices 01 0.045 
Leiomyoma 01 0.045 
PIN 02 0.09 
Total 2189 100 
 
About 50% patients of PIN had PSA levels in the range of 
10-20 ng/ml, while more than 90% patients of prostate 
cancer had PSA levels >20 ng/ml (Table II). 
 
 
 
D i s c u s s i o n  
BPH and prostate carcinoma are very common in males 
especially in geriatric age and results in lower urinary tract 
symptoms. PSA levels, DRE, and transurethral USG and 
biopsy investigations are routinely used tests for 
diagnosing prostate lesions.10 Mean age of all patients in 
the present study was 62.45±10.6 years. This is in 
agreement with the mean age reported by multiple studies 
including Khant et al. (66.9 ± 9.4 years),10 Josephine 
(65.5 years),11 and Lakhey et al. (67.6 years)12 in Indian 
and Nepalese patients respectively. In comparison, 
Jasani and colleagues reported mean age of 57.77±4.86 
years for patients with BPH and 65.82±5.6 years for 
patients with prostate cancer.13 
 
In our study, BPH was diagnosed in 1676 (76.56%) 
patients, prostatitis in 133 (6.07%), Carcinoma in 378 
(17.26%) and PIN in 02 (0.09%) patients only. Patel and 
Surti reported BPH in 68.75% patients, followed by 
carcinoma in 25% cases and prostatitis in only 1.8% 
patients.14  Shetty et al. reported BPH in only 36.6% 
patients, prostatitis in 30%, PIN in 15.3% and carcinoma 
in 18% patients.15 Gurumurthy et al. reported PIN in 
5.95% cases of prostatic lesions.16 Horninger et al. 
reported frequency of PIN in 2.91% patients and 
Anderson-Jackson et al. in 4.07% patients, 
respectively.17,18 All these studies report contrasting 
results, which are much different from our study.  
 
Serum PSA is the most widely used tumor marker but it 
cannot be used alone because it has low sensitivity and 
specificity, especially when the PSA levels are low. 
Elevation of PSA level occur in conditions such as BPH, 
prostatitis, prostatic infarct and especially in carcinoma of 
prostate. In the present study, we correlated the serum 
PSA levels with histopathological diagnosis of prostate 
lesions. We found significant association of PSA with  
 
carcinoma of prostate; PSA levels were >10 ng/ml in all 
patients with prostate carcinoma and PIN. In our study, 
PSA levels <10.0 ng/ml were found in 76.65% of the 
patients. Murthy et al. reported normal PSA levels in more 
than 40% patients who underwent prostate biopsy.19 
Another study by El-imam et al. reported PSA >4 to <10.0 
ng/ml in >70% of Sudanese patients.20 Wadgaonkar et al. 
and Gurumurthy et al. reported findings similar to our 
study with significant elevation in serum PSA levels in PIN 
and prostate carcinoma patients.21,16  
 
Serum PSA levels more than 10 ng/ml is highly indicative 
of prostate cancer. So, patients having PSA >10 ng/ml 
should be considered for surgical intervention as early as 
possible because of high probability of prostate 
carcinoma. The limitation of the present study is that we 
Table II. Association of Serum PSA Levels with common types of Histopathological Lesions 
PSA (ng/ml) BPH 
(n=1676) 
Prostatitis 
(n=133) 
Carcinoma 
(n=378) 
PIN 
(n=02) 
P-Value 
0-4.0 554 (33.05%) 15 (11.27 %) 0 (0.0 %) 0 (0.0 %) 
<0.05  
4.01-10 1050 (62.64 %) 59 (44.36 %) 0 (0.0 %) 0 (0.0 %) 
10.01-20 40 (2.4 %) 47 (35.33 %) 22 (5.82 %) 1 (50.0 %) 
20.01-100 32 (1.9 %) 11 (8.27 %) 302 (79.89 %) 1 (50.0 %) 
>100 0 (0.0 %) 1 (0.75 %) 54 (14.28 %) 0 (0.0 %) 
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did not correlate the severity/grades of prostate cancer 
(Gleason scores) with serum PSA levels. 
 
C o n c l u s i o n  
In our study, benign prostatic hyperplasia was the 
commonest prostate lesion (76.56% of the patients) and 
serum PSA levels of >10 ng/ml was found in all patients 
with prostate carcinoma and prostatic intraepithelial 
neoplasia (PIN).  
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